Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: New model for amyloid fibril formation

Amyloid

Volumn 5, Issue 3, 1998, Pages 175-187

  Schormann, Norbert ^a   Murrell, Jill R ^a   Benson, Merrill D ^a,b,c  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Crystal structures; Fibril model; Hereditary amyloidosis; Transthyretin

Indexed keywords

AMYLOID; PREALBUMIN;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; COMPUTER SIMULATION; GENETIC VARIABILITY; GENETICS; PROTEIN TERTIARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

AMYLOID; COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PREALBUMIN; PROTEIN STRUCTURE, TERTIARY; VARIATION (GENETICS);

EID: 0032153673     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129809003843     Document Type: Article

References (53)

1. Glenner GG (1980). Amyloid Deposits and Amyloidosis: The B-Fibrilloses. N Engl J Med 302, 1283-1292 and 1333-1343
2. Puchtler H, Sweat F and Levine M (1962). On the binding of Congo red by amyloid. J Histochem Cytochem 10, 355
3. Sack GH, Dumars KW, Gummerson KS, Law A and Mc Kusick VA (1981). Three forms of dominant amyloid neuropathy. Johns Hopkins Med J 149, 239
4. Benson MD (1995). Amyloidosis. In CR Sriver, AL Beaudet, WS Sly and D Valle, Eds. The Metabolic and Molecular Bases of Inherited Disease, Seventh Edition, Volume III, Chapter 139, Part 18 Connective Tissues, pp. 4159-4191. McGraw Hill Book Co., New York, NY
5. Andrade C (1952). A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75, 408-427
6. Wallace MR, Naylor SL, Kluve-Beckerman B, Long GL, McDonald L, Shows TB and Benson MD (1985). Localization of the human prealbumin gene to chromosome 18. Biochem Biophys Res Commun 129, 753-758
7. Benson MD and Uemichi T (1996). Transthyretin amyloidosis. Amyloid: Int J Exp Clin Invest 3, 44-58
8. Skinner M, Lewis WD, Jones LA, Kasirsky J, Kane K, Ju ST, Jenkins R, Falk RH, Simms RW and Cohen AS (1994). Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 120, 133-134
9. Costa RH, Lai E and Darnell JE (1986). Transcriptional control of the mouse prealbumin (transthyretin) gene: Both promoter sequences and a distinct enhancer are cell specific. Mol Cell Biol 6, 4697-4708
10. Oatley SJ, Blaney JM, Langridge R and Kollman PA (1984). Molecular mechanical studies of hormone-protein interactions: The interaction of T4 and T3 with prealbumin. Biopolymers 23, 2931
11. Monaco HL, Rizzi M and Coda A (1995). Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science 268, 1039-1041
12. Blake CCF, Geisow MF, Oatley SJ, Rerat B and Rerat C (1978). Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8Å. J Mol Biol 121, 339-356
13. Hamilton JA, Steinrauf LK, Braden BC, Liepnieks JJ, Benson MD, Holmgren G, Sandgren O and Steen L (1993). The X-ray crystal structure refinements of normal transthyretin and the amyloidogenic Val30→ Met variant to 1.7Å resolution. J Biol Chem 268, 2416-2424
14. Hamilton JA, Steinrauf LK, Braden BC, Murrell JR and Benson MD (1996). Structural changes in transthyretin produced by the Ile84Ser mutation which result in decreased affinity for retinol-binding protein. Amyloid: Int J Exp Clin Invest 3, 1-12
15. Damas AM, Ribeiro S, Lamzin VS, Palha JA and Saraiva MJ (1996). Structure of Val122Ile variant transthyretin - a cardiomyopathic mutant. Acta Cryst D52, 966-972
16. Steinrauf LK, Hamilton JA, Braden BC, Murrell JR and Benson MD (1993). X-ray crystal structure of the Ala109→ Thr variant of human transthyretin which produces euthyroid hyperthyroxinemia. J Biol Chem 268, 2425-2430
17. Wojtczak A, Luft J and Cody V (1993). Structural Aspects of Inotropic Bipyridine Binding. J Biol Chem 268, 6202-6206
18. Wojtczak A, Cody V, Luft JR and Pangborn W (1996). Structures of Human Transthyretin Complexed with Thyroxine at 2.0Å Resolution and 3′,5′-Dinitro-N-acetyl-L-thyronine at 2.2Å resolution. Acta Cryst D52, 758-765
19. Damas AM, Sebastião MP, Costa PP and Saraiva MJ (1994). A Fiber Diffraction Study of FAP Fibrils. In Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ and Young ID (eds.) Amyloid and Amyloidosis (1993), 492-494 (New York and London, Parthenon Publishing)
20. Blake CCF and Serpell L (1996). Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continous β-sheet helix. Structure 4, 989-998
21. Serpell LC, Sunde M, Fraser PE, Luther PK, Morris EP, Sandgren O, Lundgren E and Blake CCF (1995). Examination of the Structure of the Transthyretin Amyloid Fibril by Image Reconstruction from Electron Micrographs. J Mol Biol 254, 113-118
22. Jarvis JA, Munro SLA and Craik DJ (1994). Structural Analysis of Peptide Fragment 71-93 of Transthyretin by NMR Spectroscopy and Electron Microscopy: Insight into Amyloid Fibril Formation. Biochemistry 33, 33-41
23. Terry CJ, Damas AM, Oliveira P, Saraiva MJM, Alves IL, Costa PP, Matias PM, Sakaki Y and Blake CCF (1993). Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J 12, 735-741
24. Kelly JW and Lansbury PT Jr (1994). A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid: Int J Exp Clin Invest 1, 186-205
25. Serpell LC, Goldsteins G, Dacklin I, Lundgren E and Blake CCF (1996). The "edge strand" hypothesis: prediction and test of a mutational "hot-spot" on the transthyretin molecule associated with FAP amyloidogenesis. Amyloid: Int J Exp Clin Invest 3, 75-85
26. Murrell JR, Schoner RG, Liepnieks JJ, Rosen HN, Moses AC and Benson MD (1992). Production and functional analysis of normal and variant recombinant human transthyretin proteins. J Biol Chem 267, 16595-16600
27. Bailey S (1994). Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for protein crystallography. Acta Cryst D50, 760-763
28. Matthews BW (1968). Solvent content of protein crystals. J Mol Biol 33, 491-497
29. Sato M, Yamamoto M, Imada K, Katsube Y, Tanaka N and Higashi T (1992). A high-speed data-collection system for large-unit cell crystals using an imaging plate as a detector. J Appl Cryst 25, 348-357
30. Chen D, Ferrara JD, Higashi T, Jacobson RA, Klein CLD, Swepston PN, Vincent BR and Xiong L (1993-1996). 'BIOTEX Ver. 1.0', Program Suite, Molecular Structure Corporation, Houston
31. Brünger AT, Kuriyan J and Karplus M (1987). Crystallographic R factor refinement by molecular dynamics. Science 235, 458-460
32. Jones TA, Zou JY, Cowan SW and Kjeldgaard M (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Cryst A47, 110-119
33. Brünger AT (1991). Simulated Annealing in Crystallography. Annu Rev Phys Chem 42, 197-223
34. Molecular Simulations Inc. (1996). 'QUANTA96', Program Suite, San Diego, CA
35. Brünger AT (1992). The Free R Value: a Novel Statistical Quantity for Assessing the Accuracy of Crystal Structures. Nature 355, 472-474
36. Luzzati V (1952). Traitement Statistique des Erreurs dans la Determination des Structures Cristallines. Acta Cryst 5, 142-152
37. Read RJ (1986). Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Cryst A42, 140-149
38. Hubbard SJ and Thornton JM (1993). 'NACCESS', Computer Program, Department of Biochemistry and Molecular Biology, University College London
39. Lee B and Richards FM (1971). The interpretation of protein structures: estimation of static accessibility. J Mol Biol 55, 379-400
40. Laskowski RA, MacArthur MW, Moss DS and Thornton JM (1993). PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 26, 283-291
41. Kabsch W (1978). A Solution for the Best Rotation to Relate Two Sets of Vectors. Acta Cryst A32, 922-923
42. Colon W and Kelly JW (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660
43. Lai Z, Colon W and Kelly JW (1996). The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 35, 6470-6482
44. Thylen C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G and Lundgren E (1993). Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 12, 743-748
45. Goldsteins G, Andersson K, Olofsson A, Dacklin I, Edvinsson Å, Baranov V, Sandgren O, Thylen C, Hammarström S and Lundgren E (1997). Characterization of Two Highly Amyloidogenic Mutants of Transthyretin. Biochemistry 36, 5346-5352
46. Gustavsson A, Engstroem U and Westermark P (1991). Normal transthyretin and synthetic transthyretin fragments form amyloid-like fibrils in vitro. Biochem Biophys Res Comm 175, 1159-1164
47. Dwulet FE and Benson MD (1986). Characterization of a transthyretin (prealbumin) variant associated with familial amyloidotic polyneuropathy type II (Indiana/Swiss). J Clin Invest 78, 880-886
48. Wallace MR, Dwulet FE, Conneally PM and Benson MD (1986). Biochemical and molecular genetic characteristic of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 78, 6-12
49. Schormann N, Murrell JR, Liepnieks JJ and Benson MD (1995). Tertiary structure of an amyloid immunoglobulin light chain protein: A proposed model for amyloid fibril formation. Proc Natl Acad Sci USA 92, 9490-9494
50. Wetzel R (1994). Mutations and off-pathway aggregation of proteins. Trends Biotech 12, 193-198
51. Kraulis P (1991). MOLSCRIPT: a Program to Produce Both Detailed and Schematic Plot of Protein Structures. J Appl Cryst 24, 946-950
52. Kabsch W and Sander C (1983). Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637.
53. Sayle R (1995). 'RASMOL Ver. 2.6', Molecular Graphics Program, Glaxo, UK.